Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR ‐378a‐3p/ VEGFA / RGC ‐32 Axis
Cancer Medicine · 2024
DOI: 10.1002/cam4.70446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Jinli He und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: MicroRNAs, Pancreatic Neoplasms, Vascular Endothelial Growth Factor A, Metformin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, project of Jiangxi Provincial Department of Science and Technology, the project of Jiangxi Provincial Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
Background
Pancreatic cancer (PC) is a major contributor to global cancer‐related mortality. While the inhibitory effect of metformin (Met) on PC has been reported, the underlying mechanism remains elusive.
Methods
We established BxPC‐3 cell models with miR‐378a‐3p and VEGFA knockdown. The expression of miR‐378a‐3p, VEGFA, and RGC‐32 in PC and normal tissues was analyzed using GEPIA, TCGA databases. Cell proliferation, invasion, migration, and apoptosis were assessed through CCK8, Transwell, wound healing, and flow cytometry.
Results
Significantly lower expression of miR‐378a‐3p was observed in PC tissues and cells. Knockdown of miR‐378a‐3p reversed the impact of Met on cell viability in PANC‐1 and BxPC3. VEGFA emerged as a potential regulator in PC and a downstream target of miR‐378a‐3p. The interaction between VEGFA and RGC‐32 played a crucial role in PC regulation. Knockdown of VEGFA substantially reversed the impact of miR‐378a‐3p inhibitor on tumor growth and the epithelial‐mesenchymal transition (EMT) process. Moreover, knockdown of VEGFA effectively countered the influence of miR‐378a‐3p inhibitor on cell viability and the EMT process in BxPC3 cells.
Conclusions
Met exerted inhibitory effects on PC through the miR‐378a‐3p/VEGFA/RGC‐32 pathway. Strategies targeting the miR‐378a‐3p/VEGFA/RGC‐32 axis represent a novel avenue for the prevention and treatment of PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
- Department of Medical Cosmetology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
ORCID-Profile: Liang Zhu
Förderung
- National Natural Science Foundation of China
- project of Jiangxi Provincial Department of Science and Technology
- the project of Jiangxi Provincial Administration of Traditional Chinese Medicine
Zitieren
APA
He, J., Luo, Y., Ding, Y., & Zhu, L. (2024). Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR ‐378a‐3p/ VEGFA / RGC ‐32 Axis. Cancer Medicine. https://doi.org/10.1002/cam4.70446
Vancouver
He J, Luo Y, Ding Y, Zhu L. Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR ‐378a‐3p/ VEGFA / RGC ‐32 Axis. Cancer Medicine. 2024. doi:10.1002/cam4.70446
BibTeX
@article{He2024,
author = {He, Jinli and Luo, Yixing and Ding, Ying and Zhu, Liang},
title = {Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR ‐378a‐3p/ VEGFA / RGC ‐32 Axis},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70446}
}
EUVIMED